image credit: Freepik

Dyno, Roche Ink Gene Therapy Deal Worth up to $1.8B

October 14, 2020

Dyno Therapeutics, a biotech company applying artificial intelligence (AI) to gene therapy, has entered a collaboration and license agreement with Roche to apply Dyno’s CapsidMap platform for the development of next-generation adeno-associated virus (AAV) vectors for gene therapies for central nervous system (CNS) diseases and liver-directed therapies for the portfolio of both Roche and Spark Therapeutics, a member of the Roche Group.

Read More on Contract Pharma